{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:17:27Z","timestamp":1793654247706,"version":"4.5.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T00:00:00Z","timestamp":1753488000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T00:00:00Z","timestamp":1753488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Improving the outcome of relapsed or refractory diffuse large B-cell lymphoma (R\/R DLBCL) remained an unmet need. The aim of this single-center, phase 2 trial was to evaluate the efficacy and safety of genetic subtype-guided immunochemotherapy (R-ICE-X) in patients with R\/R DLBCL: R-ICE-zanubrutinib for MCD-like and BN2-like, R-ICE-lenalidomide for N1-like and NOS, R-ICE-decitabine for <jats:italic>TP53<\/jats:italic>\n            <jats:sup>Mut<\/jats:sup>, R-ICE-chidamide for EZB-like, and R-ICE-tofacitinib for ST2-like subtype. Enrolled patients were treated with assigned regimens for three cycles, and then responders were treated with autologous hematopoietic stem cell transplantation (ASCT) or 3 cycles of R-ICE-X consolidation and lenalidomide maintenance. The primary endpoint was the complete response (CR) rate. The secondary endpoints included overall response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety assessment. Between April 26, 2022, and July 31, 2024, 76 patients were enrolled, with 74 adhering to and 2 deviating from the protocol. Among all, the CR rate was 56.6% (95% CI, 45.2\u201368.0%), and the ORR was 76.3% (95% CI, 66.5\u201386.1%) at the end of induction. With a median follow-up of 19.5 months, the 2-year PFS rate was 69.3% (95% CI, 56.6\u201379.0%), and the 2-year OS rate was 88.3% (95% CI, 77.6\u201394.0%). The primary grade 3-4 adverse events were neutropenia (30%) and thrombocytopenia (25%). The presence of bulky disease and <jats:italic>CD70<\/jats:italic> mutation was linked to poor prognosis. Further gene set enrichment analysis revealed that up-regulated PI3K-AKT-mTOR signaling pathway and reduced immune cell infiltration were significantly associated with disease progression. Patients with mesenchymal or inflammatory lymphoma microenvironment subtypes benefited from R-ICE-X treatment. Our findings highlight the efficacy and safety of R-ICE-X, a mechanism-based tailored therapy, which dually targets genetic and microenvironmental alterations in R\/R DLBCL.<\/jats:p>","DOI":"10.1038\/s41392-025-02316-6","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T23:01:59Z","timestamp":1753484519000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Genetic subtype-guided immunochemotherapy in relapsed and refractory diffuse large B cell lymphoma: a phase 2 investigator-initiated nonrandomized clinical trial (GUIDANCE-06)"],"prefix":"10.1038","volume":"10","author":[{"given":"Yi-Ge","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1934-0833","authenticated-orcid":false,"given":"Qing","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng-Peng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Wen","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Meng","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6834-1616","authenticated-orcid":false,"given":"Wei-Li","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,26]]},"reference":[{"key":"2316_CR1","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/ajh.26151","volume":"96","author":"S Susanibar-Adaniya","year":"2021","unstructured":"Susanibar-Adaniya, S. & Barta, S. K. 2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management. Am. J. Hematol. 96, 617\u2013629 (2021).","journal-title":"Am. J. Hematol."},{"key":"2316_CR2","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","volume":"7","author":"M Pfreundschuh","year":"2006","unstructured":"Pfreundschuh, M. et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 7, 379\u2013391 (2006).","journal-title":"Lancet Oncol."},{"key":"2316_CR3","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","volume":"109","author":"LH Sehn","year":"2007","unstructured":"Sehn, L. H. et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109, 1857\u20131861 (2007).","journal-title":"Blood"},{"key":"2316_CR4","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump, M. et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 130, 1800\u20131808 (2017).","journal-title":"Blood"},{"key":"2316_CR5","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1182\/blood-2015-01-622084","volume":"126","author":"J Kuruvilla","year":"2015","unstructured":"Kuruvilla, J. et al. Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12. Blood 126, 733\u2013738 (2015).","journal-title":"Blood"},{"key":"2316_CR6","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","volume":"28","author":"C Gisselbrecht","year":"2010","unstructured":"Gisselbrecht, C. et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J. Clin. Oncol. 28, 4184\u20134190 (2010).","journal-title":"J. Clin. Oncol."},{"key":"2316_CR7","doi-asserted-by":"publisher","first-page":"4462","DOI":"10.1200\/JCO.2012.41.9416","volume":"30","author":"C Gisselbrecht","year":"2012","unstructured":"Gisselbrecht, C. et al. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. J. Clin. Oncol. 30, 4462\u20134469 (2012).","journal-title":"J. Clin. Oncol."},{"key":"2316_CR8","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.bbmt.2012.08.013","volume":"19","author":"JM Vose","year":"2013","unstructured":"Vose, J. M. et al. Phase II trial of 131-Iodine tositumomab with high-dose chemotherapy and autologous stem cell transplantation for relapsed diffuse large B cell lymphoma. Biol. Blood Marrow Transpl. 19, 123\u2013128 (2013).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"2316_CR9","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41392-023-01358-y","volume":"8","author":"R Shen","year":"2023","unstructured":"Shen, R. et al. Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma. Signal Transduct. Target Ther. 8, 145 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"2316_CR10","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/j.ccell.2023.09.004","volume":"41","author":"M Zhang","year":"2023","unstructured":"Zhang, M. et al. Genetic subtype-guided immunochemotherapy in diffuse large B cell lymphoma: The randomized GUIDANCE-01 trial. Cancer Cell 41, 1705\u20131716.e1705 (2023).","journal-title":"Cancer Cell"},{"key":"2316_CR11","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1182\/bloodadvances.2020003698","volume":"6","author":"H Yang","year":"2022","unstructured":"Yang, H. et al. Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma. Blood Adv. 6, 1629\u20131636 (2022).","journal-title":"Blood Adv."},{"key":"2316_CR12","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13045-016-0313-y","volume":"9","author":"J Wu","year":"2016","unstructured":"Wu, J., Liu, C., Tsui, S. T. & Liu, D. Second-generation inhibitors of Bruton tyrosine kinase. J. Hematol. Oncol. 9, 80 (2016).","journal-title":"J. Hematol. Oncol."},{"key":"2316_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.584","volume":"11","author":"M Zhang","year":"2021","unstructured":"Zhang, M. et al. Clinical efficacy and tumour microenvironment influence of decitabine plus R-CHOP in patients with newly diagnosed diffuse large B-Cell lymphoma: Phase 1\/2 and biomarker study. Clin. Transl. Med 11, e584 (2021).","journal-title":"Clin. Transl. Med"},{"key":"2316_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-021-02789-3","volume":"19","author":"X Jiang","year":"2021","unstructured":"Jiang, X. et al. Inhibition of EZH2 by chidamide exerts antileukemia activity and increases chemosensitivity through Smo\/Gli-1 pathway in acute myeloid leukemia. J. Transl. Med 19, 117 (2021).","journal-title":"J. Transl. Med"},{"key":"2316_CR15","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1136\/gutjnl-2019-318448","volume":"68","author":"S Danese","year":"2019","unstructured":"Danese, S., Argollo, M., Le Berre, C. & Peyrin-Biroulet, L. JAK selectivity for inflammatory bowel disease treatment: does it clinically matter?. Gut 68, 1893\u20131899 (2019).","journal-title":"Gut"},{"key":"2316_CR16","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1200\/JCO.2014.59.5363","volume":"33","author":"JG Gribben","year":"2015","unstructured":"Gribben, J. G., Fowler, N. & Morschhauser, F. Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma. J. Clin. Oncol. 33, 2803\u20132811 (2015).","journal-title":"J. Clin. Oncol."},{"key":"2316_CR17","doi-asserted-by":"publisher","first-page":"4010","DOI":"10.1109\/JBHI.2024.3390804","volume":"28","author":"C Qian","year":"2024","unstructured":"Qian, C. et al. Prognosis Prediction of Diffuse Large B-Cell Lymphoma in (18)F-FDG PET Images Based on Multi-Deep-Learning Models. IEEE J. Biomed. Health Inf. 28, 4010\u20134023 (2024).","journal-title":"IEEE J. Biomed. Health Inf."},{"key":"2316_CR18","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s40164-023-00432-z","volume":"12","author":"T Lu","year":"2023","unstructured":"Lu, T., Zhang, J., Xu-Monette, Z. Y. & Young, K. H. The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma. Exp. Hematol. Oncol. 12, 72 (2023).","journal-title":"Exp. Hematol. Oncol."},{"key":"2316_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-016-0711-6","volume":"14","author":"B Guo","year":"2016","unstructured":"Guo, B., Cen, H., Tan, X. & Ke, Q. Meta-analysis of the prognostic and clinical value of tumor-associated macrophages in adult classical Hodgkin lymphoma. BMC Med 14, 159 (2016).","journal-title":"BMC Med"},{"key":"2316_CR20","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/neuonc\/nox116","volume":"20","author":"L Jin","year":"2018","unstructured":"Jin, L. et al. CD70, a novel target of CAR T-cell therapy for gliomas. Neuro Oncol. 20, 55\u201365 (2018).","journal-title":"Neuro Oncol."},{"key":"2316_CR21","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/nri2526","volume":"9","author":"M Croft","year":"2009","unstructured":"Croft, M. The role of TNF superfamily members in T-cell function and diseases. Nat. Rev. Immunol. 9, 271\u2013285 (2009).","journal-title":"Nat. Rev. Immunol."},{"key":"2316_CR22","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1002\/cac2.12201","volume":"41","author":"W Deng","year":"2021","unstructured":"Deng, W. et al. CD70-targeting CAR-T cells have potential activity against CD19-negative B-cell Lymphoma. Cancer Commun. (Lond.) 41, 925\u2013929 (2021).","journal-title":"Cancer Commun. (Lond.)"},{"key":"2316_CR23","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41375-022-01749-0","volume":"37","author":"W Xu","year":"2023","unstructured":"Xu, W. et al. mTOR inhibition amplifies the anti-lymphoma effect of PI3Kbeta\/delta blockage in diffuse large B-cell lymphoma. Leukemia 37, 178\u2013189 (2023).","journal-title":"Leukemia"},{"key":"2316_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semcancer.2019.12.008","volume":"80","author":"D Tewari","year":"2022","unstructured":"Tewari, D., Patni, P., Bishayee, A., Sah, A. N. & Bishayee, A. Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy. Semin Cancer Biol. 80, 1\u201317 (2022).","journal-title":"Semin Cancer Biol."},{"key":"2316_CR25","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.ccell.2021.04.014","volume":"39","author":"A Bagaev","year":"2021","unstructured":"Bagaev, A. et al. Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell 39, 845\u2013865.e847 (2021).","journal-title":"Cancer Cell"},{"key":"2316_CR26","doi-asserted-by":"publisher","first-page":"686768","DOI":"10.3389\/fimmu.2021.686768","volume":"12","author":"M Palma","year":"2021","unstructured":"Palma, M., Mulder, T. A. & Osterborg, A. BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects. Front Immunol. 12, 686768 (2021).","journal-title":"Front Immunol."},{"key":"2316_CR27","doi-asserted-by":"publisher","first-page":"e1115940","DOI":"10.1080\/2162402X.2015.1115940","volume":"5","author":"P Otahal","year":"2016","unstructured":"Otahal, P. et al. Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells. Oncoimmunology 5, e1115940 (2016).","journal-title":"Oncoimmunology"},{"key":"2316_CR28","doi-asserted-by":"publisher","first-page":"108470","DOI":"10.1016\/j.intimp.2021.108470","volume":"103","author":"X Li","year":"2022","unstructured":"Li, X. et al. Lenalidomide attenuates post-inflammation pulmonary fibrosis through blocking NF-kappaB signaling pathway. Int Immunopharmacol. 103, 108470 (2022).","journal-title":"Int Immunopharmacol."},{"key":"2316_CR29","doi-asserted-by":"publisher","first-page":"e165694","DOI":"10.1172\/JCI165694","volume":"133","author":"VC Jiang","year":"2023","unstructured":"Jiang, V. C. et al. Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma. J. Clin. Invest 133, e165694 (2023).","journal-title":"J. Clin. Invest"},{"key":"2316_CR30","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1158\/2159-8290.CD-20-0839","volume":"11","author":"N Kotlov","year":"2021","unstructured":"Kotlov, N. et al. Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures. Cancer Discov. 11, 1468\u20131489 (2021).","journal-title":"Cancer Discov."},{"key":"2316_CR31","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.1200\/JCO.2017.73.3402","volume":"35","author":"U Vitolo","year":"2017","unstructured":"Vitolo, U. et al. Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma. J. Clin. Oncol. 35, 3529\u20133537 (2017).","journal-title":"J. Clin. Oncol."},{"key":"2316_CR32","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1182\/blood.2023020779","volume":"144","author":"AP Dabrowska-Iwanicka","year":"2024","unstructured":"Dabrowska-Iwanicka, A. P. & Nowakowski, G. S. DLBCL: Who is high risk and how should treatment be optimized?. Blood 144, 2573\u20132582 (2024).","journal-title":"Blood"},{"key":"2316_CR33","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","volume":"103","author":"CP Hans","year":"2004","unstructured":"Hans, C. P. et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103, 275\u2013282 (2004).","journal-title":"Blood"},{"key":"2316_CR34","doi-asserted-by":"publisher","first-page":"4021","DOI":"10.1182\/blood-2012-10-460063","volume":"121","author":"S Hu","year":"2013","unstructured":"Hu, S. et al. MYC\/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood 121, 4021\u20134031 (2013). quiz 4250.","journal-title":"Blood"},{"key":"2316_CR35","doi-asserted-by":"publisher","first-page":"1015081","DOI":"10.3389\/fimmu.2022.1015081","volume":"13","author":"X Yuan","year":"2022","unstructured":"Yuan, X. et al. Zanubrutinib plus salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma. Front Immunol. 13, 1015081 (2022).","journal-title":"Front Immunol."},{"key":"2316_CR36","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/bjh.12846","volume":"166","author":"T Feldman","year":"2014","unstructured":"Feldman, T. et al. Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse\/primary refractory diffuse large B-cell lymphoma. BRIT J. HAEMATOL 166, 77\u201383 (2014).","journal-title":"BRIT J. HAEMATOL"},{"key":"2316_CR37","doi-asserted-by":"publisher","first-page":"abstr. 472","DOI":"10.1002\/hon.2439_182","volume":"35","author":"Y Song","year":"2017","unstructured":"Song, Y. et al. A preliminary efficacy study of chidamide in combination with dice regimen on relapsed or refractory b cell lymphomas. Hematological Oncol. 35, abstr. 472, https:\/\/doi.org\/10.1002\/hon.2439_182 (2017).","journal-title":"Hematological Oncol."},{"key":"2316_CR38","doi-asserted-by":"publisher","first-page":"abstr. 621","DOI":"10.1182\/blood-2019-128424","volume":"134","author":"X Zhang","year":"2019","unstructured":"Zhang, X., Hu, J., Chen, Q., Zhang, M. & Young, K. Decitabine Can Improve the Efficacy of Second-Line Chemotherapy in Relapsed or Refractory Diffuse Large B Cell Lymphoma. Blood 134, abstr. 621, https:\/\/doi.org\/10.1182\/blood-2019-128424 (2019).","journal-title":"Blood"},{"key":"2316_CR39","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson, B. D. et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J. Clin. Oncol. 32, 3059\u20133068 (2014).","journal-title":"J. Clin. Oncol."},{"key":"2316_CR40","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.221","volume":"10","author":"R Shen","year":"2020","unstructured":"Shen, R. et al. Influence of oncogenic mutations and tumor microenvironment alterations on extranodal invasion in diffuse large B-cell lymphoma. Clin. Transl. Med 10, e221 (2020).","journal-title":"Clin. Transl. Med"},{"key":"2316_CR41","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","volume":"31","author":"S Anders","year":"2015","unstructured":"Anders, S., Pyl, P. T. & Huber, W. HTSeq\u2013a Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166\u2013169 (2015).","journal-title":"Bioinformatics"},{"key":"2316_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-017-1349-1","volume":"18","author":"D Aran","year":"2017","unstructured":"Aran, D., Hu, Z. & Butte, A. J. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 18, 220 (2017).","journal-title":"Genome Biol."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02316-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02316-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02316-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T08:54:25Z","timestamp":1757235265000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02316-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,26]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2316"],"URL":"https:\/\/doi.org\/10.1038\/s41392-025-02316-6","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,26]]},"assertion":[{"value":"26 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"232"}}